Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
Explore More Articles
Laser scleral microporation has high satisfaction in emmetropic presbyopes
SAN DIEGO — In this Healio Video Perspective from the ASCRS meeting, Robert Ang, MD, discusses 18-month study outcomes of laser scleral microporation in emmetropic presbyopes. “Our studies show that the patients have high patient satisfaction with laser scleral microporation treatment,” he said. “It is safe and effective, and it has great potential for this segment of …
read moreAce Vision Group Names David Lin, MD, as Chief Medical Advisor
Dr. Lin’s pioneering expertise in refractive lasers, algorithms and the medical device industry will help drive Ace Vision Group’s device development. BOSTON, Oct. 18, 2024 /PRNewswire/ — Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced the appointment of David Lin, MD as Chief Medical Advisor (CMA). Dr. Lin …
read moreMicroporation may address aging in eye
LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, AnnMarie Hipsley, DPT, PhD, discusses microporation therapeutics and its potential role in presbyopia treatment.
read more